Biotech RadarJobs updated

COMPANY

Priovant Therapeutics

HQ: Durham, NC source · priovant.com ↗

FDA-approved therapeutic company Clinical Phase 3

Location: Durham, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Dermatomyositis Cutaneous Sarcoidosis Lichen Planopilaris Posterior Uveitis Intermediate Uveitis Uveitis Non-infectious Intermediate Uveitis Non-infectious Posterior Uveitis Non-infectious Pan Uveitis Adult Type Dermatomyositis Brepocitinib

6Trials (company is sponsor)1FDA records (2 yrs)

Timeline

  1. FDA FDA New drug/biologic (novel): LISRAYA (brepocitinib tosylate) — NDA220106, Aug 27, 2026. Applicant at approval: Priovant Therapeutics, Inc. source ↗
  2. Trial start 2: A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris source ↗
  3. Trial start Phase 2/Phase 3: A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis source ↗
  4. Trial start Phase 3: A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis source ↗
  5. Trial start Phase 2: A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis source ↗
  6. Trial start Phase 2: A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis source ↗
  7. Trial start Phase 3: A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT05437263A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With DermatomyositisPhase 3CompletedOct 31, 2022Jul 17, 2025 (actual)
NCT06978725A Study of Brepocitinib in Adults With Cutaneous SarcoidosisPhase 2/Phase 3RecruitingApr 9, 2025Dec 31, 2028 (estimated)
NCT07532603A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris2RecruitingMar 19, 2026Dec 31, 2028 (estimated)
NCT06431373A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior UveitisPhase 3Active, not recruitingSep 11, 2024Sep 11, 2026 (estimated)
NCT05523765A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior UveitisPhase 2CompletedNov 14, 2022Jul 30, 2024 (actual)
NCT06433999A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant DermatomyositisPhase 2CompletedAug 28, 2024Feb 28, 2025 (actual)

FDA records (last 2 years)

Feedback